483
GlaxoSmithKline BiologicalsFDA 483 - GlaxoSmithKline Biologicals - September 13, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
GlaxoSmithKline Biologicals in Saint-Amand-Les-Eaux, France, was inspected from September 5-13, 2022, and cited for a significant record-keeping deficiency. The firm failed to maintain records verifying the routine inspection of equipment used in the manufacture of Zoster Vaccine Recombinant, Adjuvanted (Shingrix), and had not established replacement frequencies for this equipment. This indicates a lapse in quality control documentation for vaccine production.
Open in Dashboard
ID · 0ee61d1c-710e-4da3-aaa7-198abf7c893c